| 摘要: |
| ［摘要］ 目的 系统性评价ABCB1基因多态性对慢性粒细胞白血病及胃肠道间质瘤患者治疗药物伊马替尼血药浓度水平的影响，为临床个体化用药提供循证依据。方法 检索PubMed、EMBASE、Web of Sciences、Scopus、中国知网和万方数据库，搜集伊马替尼药动学通路转运体的ABCB1 C1236T、G2677T/A、C3435T基因多态性与接受伊马替尼治疗患者血药浓度的相关性研究。按照纳入及排除标准进行文献筛选、数据提取工作，并进行Meta分析。结果 共纳入ABCB1基因多态性与伊马替尼血药浓度水平相关性研究7篇，合计873例患者。Meta分析结果显示，ABCB1 C1236T中T等位基因携带者与C等位基因携带者间伊马替尼的稳态血药浓度差异有统计学意义（WMD=97.44 ng/ml，P=0.03），G2677T/A中突变纯合及杂合基因携带者与野生型基因携带者间伊马替尼血药浓度差异有统计学意义（WMD=318.27 ng/ml，P<0.01），未显示C3435T基因多态性与伊马替尼血药浓度具有显著关联性（P>0.05）。结论 ABCB1 C1236T、G2677T/A突变基因与伊马替尼血液浓度升高有关。 |
| 关键词: 伊马替尼 ABCB1 血药浓度 基因多态性 Meta分析 |
| DOI：10.3969/j.issn.1674-3806.2022.11.09 |
| 分类号:R 969 |
| 基金项目:国家自然科学基金项目（编号：82104291） |
|
| The effect of ABCB1 genetic polymorphism on the blood concentration of therapeutic drug imatinib in chronic myeloid leukemia and gastrointestinal stromal tumor patients: a meta-analysis |
|
YIN Ji-yuan, XIA Yan-zhe, CHEN Jie, et al.
|
|
Department of Pharmacy, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China
|
| Abstract: |
| ［Abstract］ Objective To systematically evaluate the effect of ABCB1 genetic polymorphism on the blood concentration of therapeutic drug imatinib in chronic myeloid leukemia and gastrointestinal stromal tumor patients, and to provide evidence-based basis for guiding clinical individualized medication. Methods PubMed, EMBASE, Web of Sciences, Scopus, China National Knowledge Internet(CNKI) and Wanfang databases were retrieved. The studies on the correlations between ABCB1 C1236T, G2677T/A and C3435T gene polymorphisms of imatinib pharmacokinetic pathway transporters and the blood concentrations in patients treated with imatinib were searched. Literature screening and data extraction were conducted according to the inclusion and exclusion criteria. Meta-analysis was performed by using Review Manager 5.4. Results A total of 7 studies on the association between ABCB1 gene polymorphism and the blood concentration of imatinib were included(eight hundred and seventy-three patients in total). The results of meta-analysis showed statistically significant difference in the steady-state blood concentration of imatinib between the carriers of T allele and the carriers of C allele in ABCB1 C1236T(WMD=97.44 ng/m, P=0.03), and between the homozygotes+heterozygotes carriers and wild-type carriers in G2677T/A(WMD=318.27 ng/ml, P<0.01), and no significant association was found between C3435T gene polymorphism and the blood concentration of imatinib(P>0.05). Conclusion The ABCB1 C1236T and G2677T/A mutated genes are associated with the elevated blood concentration of imatinib. |
| Key words: Imatinib ABCB1 Blood concentration Genetic polymorphism Meta-analysis |
